nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2B6—Ifosfamide—testicular cancer	0.121	0.179	CbGbCtD
Loperamide—CYP2C8—Ifosfamide—testicular cancer	0.0913	0.135	CbGbCtD
Loperamide—CYP2B6—Cisplatin—testicular cancer	0.0587	0.087	CbGbCtD
Loperamide—ABCB1—Dactinomycin—testicular cancer	0.0524	0.0776	CbGbCtD
Loperamide—CYP2C8—Etoposide—testicular cancer	0.0437	0.0647	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—testicular cancer	0.0393	0.0583	CbGbCtD
Loperamide—CYP3A4—Ifosfamide—testicular cancer	0.037	0.0549	CbGbCtD
Loperamide—ABCB1—Vinblastine—testicular cancer	0.0328	0.0486	CbGbCtD
Loperamide—CYP2D6—Vinblastine—testicular cancer	0.0309	0.0458	CbGbCtD
Loperamide—ABCB1—Cisplatin—testicular cancer	0.0301	0.0446	CbGbCtD
Loperamide—ABCB1—Etoposide—testicular cancer	0.0295	0.0438	CbGbCtD
Loperamide—ABCB1—Doxorubicin—testicular cancer	0.0202	0.0299	CbGbCtD
Loperamide—CYP3A4—Vinblastine—testicular cancer	0.0197	0.0291	CbGbCtD
Loperamide—ABCB1—Methotrexate—testicular cancer	0.0195	0.0289	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—testicular cancer	0.019	0.0282	CbGbCtD
Loperamide—CYP3A4—Etoposide—testicular cancer	0.0177	0.0263	CbGbCtD
Loperamide—CALM2—semen—testicular cancer	0.0123	0.143	CbGeAlD
Loperamide—CALM1—semen—testicular cancer	0.0123	0.142	CbGeAlD
Loperamide—CYP3A4—Doxorubicin—testicular cancer	0.0121	0.0179	CbGbCtD
Loperamide—Megacolon toxic—Methotrexate—testicular cancer	0.0117	0.0702	CcSEcCtD
Loperamide—POMC—gonad—testicular cancer	0.00692	0.0801	CbGeAlD
Loperamide—Ileus paralytic—Vinblastine—testicular cancer	0.00658	0.0396	CcSEcCtD
Loperamide—Megacolon—Methotrexate—testicular cancer	0.00592	0.0357	CcSEcCtD
Loperamide—POMC—female gonad—testicular cancer	0.00562	0.0651	CbGeAlD
Loperamide—POMC—testis—testicular cancer	0.00499	0.0578	CbGeAlD
Loperamide—CACNA1A—testis—testicular cancer	0.00476	0.0551	CbGeAlD
Loperamide—Ileus—Vinblastine—testicular cancer	0.00402	0.0242	CcSEcCtD
Loperamide—CALM3—seminal vesicle—testicular cancer	0.00333	0.0386	CbGeAlD
Loperamide—Ileus—Ifosfamide—testicular cancer	0.0029	0.0175	CcSEcCtD
Loperamide—CALM2—embryo—testicular cancer	0.00279	0.0322	CbGeAlD
Loperamide—CALM1—embryo—testicular cancer	0.00277	0.0321	CbGeAlD
Loperamide—CALM2—seminal vesicle—testicular cancer	0.00262	0.0303	CbGeAlD
Loperamide—Bullous eruption—Epirubicin—testicular cancer	0.0023	0.0139	CcSEcCtD
Loperamide—Bullous eruption—Doxorubicin—testicular cancer	0.00213	0.0128	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Chlorambucil—testicular cancer	0.00203	0.0122	CcSEcCtD
Loperamide—Depressed level of consciousness—Ifosfamide—testicular cancer	0.00198	0.0119	CcSEcCtD
Loperamide—CALM3—female gonad—testicular cancer	0.00196	0.0227	CbGeAlD
Loperamide—CALM2—gonad—testicular cancer	0.00189	0.0219	CbGeAlD
Loperamide—CALM1—gonad—testicular cancer	0.00188	0.0218	CbGeAlD
Loperamide—OPRM1—testis—testicular cancer	0.00188	0.0217	CbGeAlD
Loperamide—CALM3—testis—testicular cancer	0.00174	0.0201	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Chlorambucil—testicular cancer	0.00172	0.0104	CcSEcCtD
Loperamide—CALM2—female gonad—testicular cancer	0.00154	0.0178	CbGeAlD
Loperamide—CALM1—female gonad—testicular cancer	0.00153	0.0177	CbGeAlD
Loperamide—Erythema multiforme—Chlorambucil—testicular cancer	0.00148	0.00888	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Dactinomycin—testicular cancer	0.00147	0.00883	CcSEcCtD
Loperamide—Urinary retention—Ifosfamide—testicular cancer	0.00142	0.00854	CcSEcCtD
Loperamide—CYP2B6—gonad—testicular cancer	0.00141	0.0163	CbGeAlD
Loperamide—CALM2—testis—testicular cancer	0.00136	0.0158	CbGeAlD
Loperamide—CALM1—testis—testicular cancer	0.00136	0.0157	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Ifosfamide—testicular cancer	0.00134	0.00809	CcSEcCtD
Loperamide—Anaphylactoid reaction—Cisplatin—testicular cancer	0.00133	0.008	CcSEcCtD
Loperamide—Ileus—Epirubicin—testicular cancer	0.00129	0.00774	CcSEcCtD
Loperamide—CALM3—lymph node—testicular cancer	0.00126	0.0146	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Dactinomycin—testicular cancer	0.00124	0.00749	CcSEcCtD
Loperamide—Angioedema—Chlorambucil—testicular cancer	0.00124	0.00747	CcSEcCtD
Loperamide—Anaphylactoid reaction—Etoposide—testicular cancer	0.00122	0.00733	CcSEcCtD
Loperamide—Ileus—Doxorubicin—testicular cancer	0.00119	0.00716	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Ifosfamide—testicular cancer	0.00114	0.00686	CcSEcCtD
Loperamide—CYP2C8—testis—testicular cancer	0.00113	0.0131	CbGeAlD
Loperamide—ABCB1—embryo—testicular cancer	0.00111	0.0128	CbGeAlD
Loperamide—Erythema multiforme—Dactinomycin—testicular cancer	0.00106	0.00641	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Etoposide—testicular cancer	0.00106	0.00639	CcSEcCtD
Loperamide—Discomfort—Vinblastine—testicular cancer	0.00105	0.0063	CcSEcCtD
Loperamide—ABCB1—seminal vesicle—testicular cancer	0.00104	0.012	CbGeAlD
Loperamide—Urinary tract disorder—Ifosfamide—testicular cancer	0.00102	0.00614	CcSEcCtD
Loperamide—CYP2B6—testis—testicular cancer	0.00101	0.0117	CbGeAlD
Loperamide—Urethral disorder—Ifosfamide—testicular cancer	0.00101	0.00609	CcSEcCtD
Loperamide—CALM2—lymph node—testicular cancer	0.000988	0.0114	CbGeAlD
Loperamide—CALM1—lymph node—testicular cancer	0.000983	0.0114	CbGeAlD
Loperamide—Erythema multiforme—Ifosfamide—testicular cancer	0.000976	0.00588	CcSEcCtD
Loperamide—Dyspepsia—Chlorambucil—testicular cancer	0.000976	0.00588	CcSEcCtD
Loperamide—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000957	0.00576	CcSEcCtD
Loperamide—Fatigue—Chlorambucil—testicular cancer	0.000956	0.00575	CcSEcCtD
Loperamide—Depressed level of consciousness—Methotrexate—testicular cancer	0.000939	0.00565	CcSEcCtD
Loperamide—Immune system disorder—Ifosfamide—testicular cancer	0.000932	0.00561	CcSEcCtD
Loperamide—Gastrointestinal pain—Chlorambucil—testicular cancer	0.000906	0.00546	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Etoposide—testicular cancer	0.0009	0.00542	CcSEcCtD
Loperamide—Discomfort—Bleomycin—testicular cancer	0.000884	0.00532	CcSEcCtD
Loperamide—Urticaria—Chlorambucil—testicular cancer	0.000881	0.0053	CcSEcCtD
Loperamide—Urinary tract disorder—Cisplatin—testicular cancer	0.000879	0.00529	CcSEcCtD
Loperamide—Abdominal pain—Chlorambucil—testicular cancer	0.000876	0.00528	CcSEcCtD
Loperamide—Urethral disorder—Cisplatin—testicular cancer	0.000872	0.00525	CcSEcCtD
Loperamide—Constipation—Vinblastine—testicular cancer	0.000869	0.00523	CcSEcCtD
Loperamide—Anaphylactic shock—Bleomycin—testicular cancer	0.000858	0.00517	CcSEcCtD
Loperamide—CYP2D6—female gonad—testicular cancer	0.000849	0.00983	CbGeAlD
Loperamide—Gastrointestinal pain—Vinblastine—testicular cancer	0.000831	0.005	CcSEcCtD
Loperamide—Discomfort—Dactinomycin—testicular cancer	0.000825	0.00497	CcSEcCtD
Loperamide—Angioedema—Ifosfamide—testicular cancer	0.000821	0.00494	CcSEcCtD
Loperamide—Hypersensitivity—Chlorambucil—testicular cancer	0.000817	0.00492	CcSEcCtD
Loperamide—Urinary tract disorder—Etoposide—testicular cancer	0.000805	0.00485	CcSEcCtD
Loperamide—Immune system disorder—Cisplatin—testicular cancer	0.000804	0.00484	CcSEcCtD
Loperamide—Abdominal pain—Vinblastine—testicular cancer	0.000803	0.00483	CcSEcCtD
Loperamide—Urethral disorder—Etoposide—testicular cancer	0.000799	0.00481	CcSEcCtD
Loperamide—Asthenia—Chlorambucil—testicular cancer	0.000795	0.00479	CcSEcCtD
Loperamide—Pruritus—Chlorambucil—testicular cancer	0.000784	0.00472	CcSEcCtD
Loperamide—Erythema multiforme—Etoposide—testicular cancer	0.000771	0.00464	CcSEcCtD
Loperamide—Flatulence—Cisplatin—testicular cancer	0.000763	0.0046	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00076	0.00457	CcSEcCtD
Loperamide—Diarrhoea—Chlorambucil—testicular cancer	0.000758	0.00457	CcSEcCtD
Loperamide—Discomfort—Ifosfamide—testicular cancer	0.000756	0.00455	CcSEcCtD
Loperamide—CYP2D6—testis—testicular cancer	0.000753	0.00872	CbGeAlD
Loperamide—ABCB1—gonad—testicular cancer	0.000751	0.0087	CbGeAlD
Loperamide—Hypersensitivity—Vinblastine—testicular cancer	0.000748	0.00451	CcSEcCtD
Loperamide—Immune system disorder—Etoposide—testicular cancer	0.000736	0.00443	CcSEcCtD
Loperamide—Anaphylactic shock—Ifosfamide—testicular cancer	0.000733	0.00441	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methotrexate—testicular cancer	0.000729	0.00439	CcSEcCtD
Loperamide—Asthenia—Vinblastine—testicular cancer	0.000729	0.00439	CcSEcCtD
Loperamide—Nervous system disorder—Ifosfamide—testicular cancer	0.000719	0.00433	CcSEcCtD
Loperamide—Skin disorder—Ifosfamide—testicular cancer	0.000712	0.00429	CcSEcCtD
Loperamide—Vomiting—Chlorambucil—testicular cancer	0.000705	0.00424	CcSEcCtD
Loperamide—Diarrhoea—Vinblastine—testicular cancer	0.000695	0.00418	CcSEcCtD
Loperamide—Dermatitis bullous—Epirubicin—testicular cancer	0.000691	0.00416	CcSEcCtD
Loperamide—Fatigue—Dactinomycin—testicular cancer	0.00069	0.00415	CcSEcCtD
Loperamide—Anaphylactoid reaction—Epirubicin—testicular cancer	0.000682	0.00411	CcSEcCtD
Loperamide—Urticaria—Bleomycin—testicular cancer	0.000681	0.0041	CcSEcCtD
Loperamide—Dizziness—Vinblastine—testicular cancer	0.000672	0.00404	CcSEcCtD
Loperamide—Nausea—Chlorambucil—testicular cancer	0.000658	0.00396	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000655	0.00394	CcSEcCtD
Loperamide—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000654	0.00394	CcSEcCtD
Loperamide—Somnolence—Ifosfamide—testicular cancer	0.000652	0.00392	CcSEcCtD
Loperamide—Discomfort—Cisplatin—testicular cancer	0.000651	0.00392	CcSEcCtD
Loperamide—Vomiting—Vinblastine—testicular cancer	0.000646	0.00389	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—testicular cancer	0.000639	0.00385	CcSEcCtD
Loperamide—Headache—Vinblastine—testicular cancer	0.000636	0.00383	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000635	0.00383	CcSEcCtD
Loperamide—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000633	0.00381	CcSEcCtD
Loperamide—Abdominal pain—Dactinomycin—testicular cancer	0.000632	0.00381	CcSEcCtD
Loperamide—Fatigue—Ifosfamide—testicular cancer	0.000632	0.00381	CcSEcCtD
Loperamide—Anaphylactic shock—Cisplatin—testicular cancer	0.000632	0.00381	CcSEcCtD
Loperamide—Hypersensitivity—Bleomycin—testicular cancer	0.000632	0.00381	CcSEcCtD
Loperamide—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.000631	0.0038	CcSEcCtD
Loperamide—Constipation—Ifosfamide—testicular cancer	0.000627	0.00378	CcSEcCtD
Loperamide—Loss of consciousness—Etoposide—testicular cancer	0.000624	0.00376	CcSEcCtD
Loperamide—Nervous system disorder—Cisplatin—testicular cancer	0.00062	0.00373	CcSEcCtD
Loperamide—Asthenia—Bleomycin—testicular cancer	0.000615	0.00371	CcSEcCtD
Loperamide—Skin disorder—Cisplatin—testicular cancer	0.000614	0.0037	CcSEcCtD
Loperamide—ABCB1—female gonad—testicular cancer	0.00061	0.00707	CbGeAlD
Loperamide—Pruritus—Bleomycin—testicular cancer	0.000607	0.00365	CcSEcCtD
Loperamide—Nausea—Vinblastine—testicular cancer	0.000603	0.00363	CcSEcCtD
Loperamide—Abdominal pain upper—Epirubicin—testicular cancer	0.000603	0.00363	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.0006	0.00361	CcSEcCtD
Loperamide—Gastrointestinal pain—Ifosfamide—testicular cancer	0.0006	0.00361	CcSEcCtD
Loperamide—Discomfort—Etoposide—testicular cancer	0.000597	0.00359	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000595	0.00358	CcSEcCtD
Loperamide—Hypersensitivity—Dactinomycin—testicular cancer	0.000589	0.00355	CcSEcCtD
Loperamide—Urticaria—Ifosfamide—testicular cancer	0.000582	0.00351	CcSEcCtD
Loperamide—Abdominal pain—Ifosfamide—testicular cancer	0.00058	0.00349	CcSEcCtD
Loperamide—Anaphylactic shock—Etoposide—testicular cancer	0.000579	0.00349	CcSEcCtD
Loperamide—Abdominal distension—Epirubicin—testicular cancer	0.000575	0.00346	CcSEcCtD
Loperamide—Asthenia—Dactinomycin—testicular cancer	0.000574	0.00346	CcSEcCtD
Loperamide—Skin disorder—Etoposide—testicular cancer	0.000562	0.00339	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—testicular cancer	0.000558	0.00336	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00055	0.00331	CcSEcCtD
Loperamide—Diarrhoea—Dactinomycin—testicular cancer	0.000547	0.0033	CcSEcCtD
Loperamide—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000546	0.00329	CcSEcCtD
Loperamide—Vomiting—Bleomycin—testicular cancer	0.000545	0.00328	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—testicular cancer	0.000544	0.00327	CcSEcCtD
Loperamide—ABCB1—testis—testicular cancer	0.000541	0.00627	CbGeAlD
Loperamide—Rash—Bleomycin—testicular cancer	0.000541	0.00326	CcSEcCtD
Loperamide—Dermatitis—Bleomycin—testicular cancer	0.00054	0.00325	CcSEcCtD
Loperamide—Hypersensitivity—Ifosfamide—testicular cancer	0.00054	0.00325	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000539	0.00325	CcSEcCtD
Loperamide—Abdominal distension—Doxorubicin—testicular cancer	0.000532	0.0032	CcSEcCtD
Loperamide—Asthenia—Ifosfamide—testicular cancer	0.000526	0.00317	CcSEcCtD
Loperamide—Pruritus—Ifosfamide—testicular cancer	0.000519	0.00312	CcSEcCtD
Loperamide—Somnolence—Etoposide—testicular cancer	0.000515	0.0031	CcSEcCtD
Loperamide—Nausea—Bleomycin—testicular cancer	0.00051	0.00307	CcSEcCtD
Loperamide—Drowsiness—Epirubicin—testicular cancer	0.000509	0.00306	CcSEcCtD
Loperamide—Vomiting—Dactinomycin—testicular cancer	0.000509	0.00306	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000505	0.00304	CcSEcCtD
Loperamide—Rash—Dactinomycin—testicular cancer	0.000504	0.00304	CcSEcCtD
Loperamide—Diarrhoea—Ifosfamide—testicular cancer	0.000502	0.00302	CcSEcCtD
Loperamide—Gastrointestinal disorder—Etoposide—testicular cancer	0.0005	0.00301	CcSEcCtD
Loperamide—Fatigue—Etoposide—testicular cancer	0.000499	0.00301	CcSEcCtD
Loperamide—Constipation—Etoposide—testicular cancer	0.000495	0.00298	CcSEcCtD
Loperamide—Dizziness—Ifosfamide—testicular cancer	0.000485	0.00292	CcSEcCtD
Loperamide—Urinary tract disorder—Methotrexate—testicular cancer	0.000482	0.0029	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—testicular cancer	0.000479	0.00288	CcSEcCtD
Loperamide—Nausea—Dactinomycin—testicular cancer	0.000475	0.00286	CcSEcCtD
Loperamide—Gastrointestinal pain—Etoposide—testicular cancer	0.000473	0.00285	CcSEcCtD
Loperamide—Drowsiness—Doxorubicin—testicular cancer	0.000471	0.00284	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000467	0.00281	CcSEcCtD
Loperamide—Vomiting—Ifosfamide—testicular cancer	0.000466	0.00281	CcSEcCtD
Loperamide—Hypersensitivity—Cisplatin—testicular cancer	0.000466	0.0028	CcSEcCtD
Loperamide—Rash—Ifosfamide—testicular cancer	0.000462	0.00278	CcSEcCtD
Loperamide—Dermatitis—Ifosfamide—testicular cancer	0.000462	0.00278	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—testicular cancer	0.000462	0.00278	CcSEcCtD
Loperamide—Urticaria—Etoposide—testicular cancer	0.00046	0.00277	CcSEcCtD
Loperamide—Abdominal pain—Etoposide—testicular cancer	0.000458	0.00276	CcSEcCtD
Loperamide—Asthenia—Cisplatin—testicular cancer	0.000453	0.00273	CcSEcCtD
Loperamide—Urinary tract disorder—Epirubicin—testicular cancer	0.000451	0.00272	CcSEcCtD
Loperamide—Urethral disorder—Epirubicin—testicular cancer	0.000448	0.0027	CcSEcCtD
Loperamide—Immune system disorder—Methotrexate—testicular cancer	0.000441	0.00266	CcSEcCtD
Loperamide—Nausea—Ifosfamide—testicular cancer	0.000435	0.00262	CcSEcCtD
Loperamide—Diarrhoea—Cisplatin—testicular cancer	0.000432	0.0026	CcSEcCtD
Loperamide—Erythema multiforme—Epirubicin—testicular cancer	0.000432	0.0026	CcSEcCtD
Loperamide—Hypersensitivity—Etoposide—testicular cancer	0.000427	0.00257	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—testicular cancer	0.000417	0.00251	CcSEcCtD
Loperamide—Asthenia—Etoposide—testicular cancer	0.000415	0.0025	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—testicular cancer	0.000414	0.0025	CcSEcCtD
Loperamide—Immune system disorder—Epirubicin—testicular cancer	0.000413	0.00248	CcSEcCtD
Loperamide—Pruritus—Etoposide—testicular cancer	0.00041	0.00247	CcSEcCtD
Loperamide—Vomiting—Cisplatin—testicular cancer	0.000402	0.00242	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—testicular cancer	0.0004	0.00241	CcSEcCtD
Loperamide—Rash—Cisplatin—testicular cancer	0.000399	0.0024	CcSEcCtD
Loperamide—Dermatitis—Cisplatin—testicular cancer	0.000398	0.0024	CcSEcCtD
Loperamide—Diarrhoea—Etoposide—testicular cancer	0.000396	0.00239	CcSEcCtD
Loperamide—ABCB1—lymph node—testicular cancer	0.000392	0.00454	CbGeAlD
Loperamide—Flatulence—Epirubicin—testicular cancer	0.000392	0.00236	CcSEcCtD
Loperamide—Dizziness—Etoposide—testicular cancer	0.000383	0.00231	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—testicular cancer	0.000382	0.0023	CcSEcCtD
Loperamide—Nausea—Cisplatin—testicular cancer	0.000375	0.00226	CcSEcCtD
Loperamide—Vomiting—Etoposide—testicular cancer	0.000368	0.00222	CcSEcCtD
Loperamide—Rash—Etoposide—testicular cancer	0.000365	0.0022	CcSEcCtD
Loperamide—Dermatitis—Etoposide—testicular cancer	0.000365	0.0022	CcSEcCtD
Loperamide—Headache—Etoposide—testicular cancer	0.000363	0.00218	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—testicular cancer	0.000363	0.00218	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000359	0.00216	CcSEcCtD
Loperamide—Discomfort—Methotrexate—testicular cancer	0.000357	0.00215	CcSEcCtD
Loperamide—Loss of consciousness—Epirubicin—testicular cancer	0.00035	0.0021	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—testicular cancer	0.000347	0.00209	CcSEcCtD
Loperamide—Nausea—Etoposide—testicular cancer	0.000344	0.00207	CcSEcCtD
Loperamide—Nervous system disorder—Methotrexate—testicular cancer	0.00034	0.00205	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—testicular cancer	0.000337	0.00203	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000336	0.00202	CcSEcCtD
Loperamide—Discomfort—Epirubicin—testicular cancer	0.000335	0.00201	CcSEcCtD
Loperamide—Dry mouth—Epirubicin—testicular cancer	0.000331	0.00199	CcSEcCtD
Loperamide—Anaphylactic shock—Epirubicin—testicular cancer	0.000325	0.00195	CcSEcCtD
Loperamide—Loss of consciousness—Doxorubicin—testicular cancer	0.000323	0.00195	CcSEcCtD
Loperamide—Nervous system disorder—Epirubicin—testicular cancer	0.000318	0.00192	CcSEcCtD
Loperamide—Skin disorder—Epirubicin—testicular cancer	0.000315	0.0019	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000311	0.00187	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—testicular cancer	0.00031	0.00186	CcSEcCtD
Loperamide—Somnolence—Methotrexate—testicular cancer	0.000308	0.00186	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—testicular cancer	0.000306	0.00185	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—testicular cancer	0.000305	0.00184	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—testicular cancer	0.0003	0.00181	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000299	0.0018	CcSEcCtD
Loperamide—Fatigue—Methotrexate—testicular cancer	0.000299	0.0018	CcSEcCtD
Loperamide—Nervous system disorder—Doxorubicin—testicular cancer	0.000295	0.00177	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—testicular cancer	0.000292	0.00176	CcSEcCtD
Loperamide—Somnolence—Epirubicin—testicular cancer	0.000289	0.00174	CcSEcCtD
Loperamide—Dyspepsia—Epirubicin—testicular cancer	0.000286	0.00172	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—testicular cancer	0.000284	0.00171	CcSEcCtD
Loperamide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00028	0.00169	CcSEcCtD
Loperamide—Fatigue—Epirubicin—testicular cancer	0.00028	0.00169	CcSEcCtD
Loperamide—Constipation—Epirubicin—testicular cancer	0.000278	0.00167	CcSEcCtD
Loperamide—Urticaria—Methotrexate—testicular cancer	0.000276	0.00166	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—testicular cancer	0.000274	0.00165	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—testicular cancer	0.000267	0.00161	CcSEcCtD
Loperamide—Gastrointestinal pain—Epirubicin—testicular cancer	0.000265	0.0016	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—testicular cancer	0.000264	0.00159	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000259	0.00156	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—testicular cancer	0.000259	0.00156	CcSEcCtD
Loperamide—Urticaria—Epirubicin—testicular cancer	0.000258	0.00155	CcSEcCtD
Loperamide—Constipation—Doxorubicin—testicular cancer	0.000257	0.00155	CcSEcCtD
Loperamide—Abdominal pain—Epirubicin—testicular cancer	0.000257	0.00155	CcSEcCtD
Loperamide—Hypersensitivity—Methotrexate—testicular cancer	0.000256	0.00154	CcSEcCtD
Loperamide—Asthenia—Methotrexate—testicular cancer	0.000249	0.0015	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000246	0.00148	CcSEcCtD
Loperamide—Pruritus—Methotrexate—testicular cancer	0.000245	0.00148	CcSEcCtD
Loperamide—Hypersensitivity—Epirubicin—testicular cancer	0.000239	0.00144	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—testicular cancer	0.000239	0.00144	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—testicular cancer	0.000237	0.00143	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—testicular cancer	0.000237	0.00143	CcSEcCtD
Loperamide—Asthenia—Epirubicin—testicular cancer	0.000233	0.0014	CcSEcCtD
Loperamide—POMC—Metabolism of proteins—MMP2—testicular cancer	0.00023	0.00314	CbGpPWpGaD
Loperamide—Pruritus—Epirubicin—testicular cancer	0.00023	0.00138	CcSEcCtD
Loperamide—Dizziness—Methotrexate—testicular cancer	0.000229	0.00138	CcSEcCtD
Loperamide—CALM2—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000226	0.00309	CbGpPWpGaD
Loperamide—CALM1—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000226	0.00309	CbGpPWpGaD
Loperamide—Diarrhoea—Epirubicin—testicular cancer	0.000222	0.00134	CcSEcCtD
Loperamide—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.000221	0.00303	CbGpPWpGaD
Loperamide—Hypersensitivity—Doxorubicin—testicular cancer	0.000221	0.00133	CcSEcCtD
Loperamide—OPRD1—Signaling Pathways—INSL3—testicular cancer	0.000221	0.00302	CbGpPWpGaD
Loperamide—Vomiting—Methotrexate—testicular cancer	0.000221	0.00133	CcSEcCtD
Loperamide—CALM3—Downstream signal transduction—KITLG—testicular cancer	0.00022	0.00301	CbGpPWpGaD
Loperamide—Rash—Methotrexate—testicular cancer	0.000219	0.00132	CcSEcCtD
Loperamide—CALM3—Signaling by FGFR—KITLG—testicular cancer	0.000219	0.00299	CbGpPWpGaD
Loperamide—Dermatitis—Methotrexate—testicular cancer	0.000218	0.00132	CcSEcCtD
Loperamide—CALM3—Signaling by ERBB2—KITLG—testicular cancer	0.000218	0.00298	CbGpPWpGaD
Loperamide—Headache—Methotrexate—testicular cancer	0.000217	0.00131	CcSEcCtD
Loperamide—CALM3—DAP12 signaling—KITLG—testicular cancer	0.000217	0.00296	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000216	0.00296	CbGpPWpGaD
Loperamide—Asthenia—Doxorubicin—testicular cancer	0.000215	0.0013	CcSEcCtD
Loperamide—Dizziness—Epirubicin—testicular cancer	0.000215	0.00129	CcSEcCtD
Loperamide—CALM1—Downstream signal transduction—KITLG—testicular cancer	0.000213	0.00291	CbGpPWpGaD
Loperamide—CALM2—Downstream signal transduction—KITLG—testicular cancer	0.000213	0.00291	CbGpPWpGaD
Loperamide—Pruritus—Doxorubicin—testicular cancer	0.000212	0.00128	CcSEcCtD
Loperamide—POMC—Metabolism—STK11—testicular cancer	0.000212	0.00289	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR—KITLG—testicular cancer	0.000212	0.00289	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR—KITLG—testicular cancer	0.000212	0.00289	CbGpPWpGaD
Loperamide—CALM2—Signaling by ERBB2—KITLG—testicular cancer	0.00021	0.00288	CbGpPWpGaD
Loperamide—CALM1—Signaling by ERBB2—KITLG—testicular cancer	0.00021	0.00288	CbGpPWpGaD
Loperamide—CALM2—DAP12 signaling—KITLG—testicular cancer	0.000209	0.00286	CbGpPWpGaD
Loperamide—CALM1—DAP12 signaling—KITLG—testicular cancer	0.000209	0.00286	CbGpPWpGaD
Loperamide—Vomiting—Epirubicin—testicular cancer	0.000206	0.00124	CcSEcCtD
Loperamide—Nausea—Methotrexate—testicular cancer	0.000206	0.00124	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—testicular cancer	0.000205	0.00124	CcSEcCtD
Loperamide—Rash—Epirubicin—testicular cancer	0.000205	0.00123	CcSEcCtD
Loperamide—Dermatitis—Epirubicin—testicular cancer	0.000204	0.00123	CcSEcCtD
Loperamide—CALM3—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000204	0.00279	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR in disease—KITLG—testicular cancer	0.000204	0.00279	CbGpPWpGaD
Loperamide—CALM3—DAP12 interactions—KITLG—testicular cancer	0.000204	0.00279	CbGpPWpGaD
Loperamide—Headache—Epirubicin—testicular cancer	0.000203	0.00122	CcSEcCtD
Loperamide—CALM3—Signaling by EGFR—KITLG—testicular cancer	0.000202	0.00276	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.0002	0.00274	CbGpPWpGaD
Loperamide—CALM3—Signaling by PDGF—KITLG—testicular cancer	0.000199	0.00272	CbGpPWpGaD
Loperamide—Dizziness—Doxorubicin—testicular cancer	0.000199	0.0012	CcSEcCtD
Loperamide—CALM1—Signaling by FGFR in disease—KITLG—testicular cancer	0.000197	0.0027	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR in disease—KITLG—testicular cancer	0.000197	0.0027	CbGpPWpGaD
Loperamide—CALM1—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000197	0.0027	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—KITLG—testicular cancer	0.000197	0.0027	CbGpPWpGaD
Loperamide—CALM2—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000197	0.0027	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—KITLG—testicular cancer	0.000197	0.0027	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR—KITLG—testicular cancer	0.000195	0.00267	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR—KITLG—testicular cancer	0.000195	0.00267	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000194	0.00265	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000194	0.00265	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—INSL3—testicular cancer	0.000193	0.00265	CbGpPWpGaD
Loperamide—Nausea—Epirubicin—testicular cancer	0.000193	0.00116	CcSEcCtD
Loperamide—CALM1—Signaling by PDGF—KITLG—testicular cancer	0.000193	0.00264	CbGpPWpGaD
Loperamide—CALM2—Signaling by PDGF—KITLG—testicular cancer	0.000193	0.00264	CbGpPWpGaD
Loperamide—Vomiting—Doxorubicin—testicular cancer	0.000191	0.00115	CcSEcCtD
Loperamide—Rash—Doxorubicin—testicular cancer	0.000189	0.00114	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—testicular cancer	0.000189	0.00114	CcSEcCtD
Loperamide—CALM3—B Cell Activation—KITLG—testicular cancer	0.000189	0.00258	CbGpPWpGaD
Loperamide—Headache—Doxorubicin—testicular cancer	0.000188	0.00113	CcSEcCtD
Loperamide—CACNA1A—Metabolism—STK11—testicular cancer	0.000183	0.0025	CbGpPWpGaD
Loperamide—CALM2—B Cell Activation—KITLG—testicular cancer	0.000182	0.00249	CbGpPWpGaD
Loperamide—CALM1—B Cell Activation—KITLG—testicular cancer	0.000182	0.00249	CbGpPWpGaD
Loperamide—CALM3—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.000181	0.00248	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.00018	0.00247	CbGpPWpGaD
Loperamide—Nausea—Doxorubicin—testicular cancer	0.000178	0.00107	CcSEcCtD
Loperamide—POMC—Signaling Pathways—H2AFZ—testicular cancer	0.000178	0.00243	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—STK11—testicular cancer	0.000177	0.00242	CbGpPWpGaD
Loperamide—CALM2—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.000176	0.0024	CbGpPWpGaD
Loperamide—CALM1—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.000176	0.0024	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000175	0.00239	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000175	0.00239	CbGpPWpGaD
Loperamide—CALM3—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000174	0.00238	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—INSL3—testicular cancer	0.000171	0.00234	CbGpPWpGaD
Loperamide—CALM3—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000169	0.0023	CbGpPWpGaD
Loperamide—CALM1—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000168	0.0023	CbGpPWpGaD
Loperamide—CALM2—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000168	0.0023	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—INSL3—testicular cancer	0.000166	0.00227	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—INSL3—testicular cancer	0.000166	0.00227	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—KITLG—testicular cancer	0.000164	0.00224	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—INSL3—testicular cancer	0.000164	0.00224	CbGpPWpGaD
Loperamide—CALM3—Downstream signal transduction—FGFR3—testicular cancer	0.000163	0.00223	CbGpPWpGaD
Loperamide—CALM2—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000163	0.00223	CbGpPWpGaD
Loperamide—CALM1—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000163	0.00223	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR—FGFR3—testicular cancer	0.000163	0.00222	CbGpPWpGaD
Loperamide—CALM3—Signaling by ERBB2—FGFR3—testicular cancer	0.000162	0.00221	CbGpPWpGaD
Loperamide—CALM3—DAP12 signaling—FGFR3—testicular cancer	0.000161	0.0022	CbGpPWpGaD
Loperamide—CALM3—Downstream signaling of activated FGFR—KIT—testicular cancer	0.00016	0.00218	CbGpPWpGaD
Loperamide—CALM1—Downstream signal transduction—FGFR3—testicular cancer	0.000158	0.00216	CbGpPWpGaD
Loperamide—CALM2—Downstream signal transduction—FGFR3—testicular cancer	0.000158	0.00216	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR—FGFR3—testicular cancer	0.000157	0.00215	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR—FGFR3—testicular cancer	0.000157	0.00215	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000157	0.00215	CbGpPWpGaD
Loperamide—CALM2—Signaling by ERBB2—FGFR3—testicular cancer	0.000156	0.00214	CbGpPWpGaD
Loperamide—CALM1—Signaling by ERBB2—FGFR3—testicular cancer	0.000156	0.00214	CbGpPWpGaD
Loperamide—CALM1—DAP12 signaling—FGFR3—testicular cancer	0.000156	0.00213	CbGpPWpGaD
Loperamide—CALM2—DAP12 signaling—FGFR3—testicular cancer	0.000156	0.00213	CbGpPWpGaD
Loperamide—CALM2—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000154	0.00211	CbGpPWpGaD
Loperamide—CALM1—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000154	0.00211	CbGpPWpGaD
Loperamide—CALM3—DAP12 interactions—FGFR3—testicular cancer	0.000151	0.00207	CbGpPWpGaD
Loperamide—CALM3—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000151	0.00207	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000151	0.00207	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR—FGFR3—testicular cancer	0.00015	0.00205	CbGpPWpGaD
Loperamide—CALM3—Downstream signal transduction—KIT—testicular cancer	0.00015	0.00205	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR—KIT—testicular cancer	0.000149	0.00204	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000149	0.00203	CbGpPWpGaD
Loperamide—CALM3—Signaling by ERBB2—KIT—testicular cancer	0.000148	0.00203	CbGpPWpGaD
Loperamide—CALM3—Signaling by PDGF—FGFR3—testicular cancer	0.000148	0.00203	CbGpPWpGaD
Loperamide—CALM3—DAP12 signaling—KIT—testicular cancer	0.000148	0.00202	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000146	0.002	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—FGFR3—testicular cancer	0.000146	0.002	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000146	0.002	CbGpPWpGaD
Loperamide—CALM2—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000146	0.002	CbGpPWpGaD
Loperamide—CALM1—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000146	0.002	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—FGFR3—testicular cancer	0.000146	0.002	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR—FGFR3—testicular cancer	0.000145	0.00199	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR—FGFR3—testicular cancer	0.000145	0.00199	CbGpPWpGaD
Loperamide—CALM2—Downstream signal transduction—KIT—testicular cancer	0.000145	0.00198	CbGpPWpGaD
Loperamide—CALM1—Downstream signal transduction—KIT—testicular cancer	0.000145	0.00198	CbGpPWpGaD
Loperamide—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000145	0.00198	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR—KIT—testicular cancer	0.000144	0.00197	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR—KIT—testicular cancer	0.000144	0.00197	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000144	0.00197	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000144	0.00197	CbGpPWpGaD
Loperamide—CALM1—Signaling by ERBB2—KIT—testicular cancer	0.000144	0.00196	CbGpPWpGaD
Loperamide—CALM2—Signaling by ERBB2—KIT—testicular cancer	0.000144	0.00196	CbGpPWpGaD
Loperamide—CALM2—Signaling by PDGF—FGFR3—testicular cancer	0.000143	0.00196	CbGpPWpGaD
Loperamide—CALM1—Signaling by PDGF—FGFR3—testicular cancer	0.000143	0.00196	CbGpPWpGaD
Loperamide—CALM1—DAP12 signaling—KIT—testicular cancer	0.000143	0.00195	CbGpPWpGaD
Loperamide—CALM2—DAP12 signaling—KIT—testicular cancer	0.000143	0.00195	CbGpPWpGaD
Loperamide—CALM3—B Cell Activation—FGFR3—testicular cancer	0.00014	0.00192	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR in disease—KIT—testicular cancer	0.000139	0.0019	CbGpPWpGaD
Loperamide—CALM3—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000139	0.0019	CbGpPWpGaD
Loperamide—CALM3—DAP12 interactions—KIT—testicular cancer	0.000139	0.0019	CbGpPWpGaD
Loperamide—CALM3—Signaling by Wnt—H2AFZ—testicular cancer	0.000139	0.0019	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—KITLG—testicular cancer	0.000139	0.0019	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR—KIT—testicular cancer	0.000138	0.00188	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000137	0.00187	CbGpPWpGaD
Loperamide—CALM3—Signaling by PDGF—KIT—testicular cancer	0.000136	0.00186	CbGpPWpGaD
Loperamide—CALM2—B Cell Activation—FGFR3—testicular cancer	0.000136	0.00185	CbGpPWpGaD
Loperamide—CALM1—B Cell Activation—FGFR3—testicular cancer	0.000136	0.00185	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—KIT—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM2—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—KIT—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM1—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR in disease—KIT—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR in disease—KIT—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM2—Signaling by Wnt—H2AFZ—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM1—Signaling by Wnt—H2AFZ—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—KITLG—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—KITLG—testicular cancer	0.000134	0.00184	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000134	0.00183	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR—KIT—testicular cancer	0.000133	0.00182	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR—KIT—testicular cancer	0.000133	0.00182	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000132	0.00181	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000132	0.00181	CbGpPWpGaD
Loperamide—CALM2—Signaling by PDGF—KIT—testicular cancer	0.000132	0.0018	CbGpPWpGaD
Loperamide—CALM1—Signaling by PDGF—KIT—testicular cancer	0.000132	0.0018	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—BCL10—testicular cancer	0.000131	0.0018	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.00013	0.00177	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.00013	0.00177	CbGpPWpGaD
Loperamide—CALM3—B Cell Activation—KIT—testicular cancer	0.000129	0.00176	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—BCL10—testicular cancer	0.000127	0.00174	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—BCL10—testicular cancer	0.000127	0.00174	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—BCL10—testicular cancer	0.000126	0.00172	CbGpPWpGaD
Loperamide—CALM2—B Cell Activation—KIT—testicular cancer	0.000124	0.0017	CbGpPWpGaD
Loperamide—CALM1—B Cell Activation—KIT—testicular cancer	0.000124	0.0017	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000123	0.00168	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—BCL10—testicular cancer	0.000122	0.00167	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—BCL10—testicular cancer	0.000122	0.00167	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—FGFR3—testicular cancer	0.000122	0.00166	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000119	0.00163	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000119	0.00163	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—KIT—testicular cancer	0.000112	0.00153	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000104	0.00142	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—FGFR3—testicular cancer	0.000103	0.00141	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—INSL3—testicular cancer	0.000101	0.00138	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—FGFR3—testicular cancer	9.98e-05	0.00136	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—FGFR3—testicular cancer	9.98e-05	0.00136	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—INSL3—testicular cancer	9.79e-05	0.00134	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—INSL3—testicular cancer	9.79e-05	0.00134	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—KIT—testicular cancer	9.47e-05	0.0013	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—KIT—testicular cancer	9.16e-05	0.00125	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—KIT—testicular cancer	9.16e-05	0.00125	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—KITLG—testicular cancer	7.92e-05	0.00108	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—KITLG—testicular cancer	7.66e-05	0.00105	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—KITLG—testicular cancer	7.66e-05	0.00105	CbGpPWpGaD
Loperamide—CALM3—Immune System—BCL10—testicular cancer	7.65e-05	0.00105	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—KITLG—testicular cancer	7.6e-05	0.00104	CbGpPWpGaD
Loperamide—CALM1—Immune System—BCL10—testicular cancer	7.4e-05	0.00101	CbGpPWpGaD
Loperamide—CALM2—Immune System—BCL10—testicular cancer	7.4e-05	0.00101	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KITLG—testicular cancer	7.35e-05	0.00101	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—KITLG—testicular cancer	7.35e-05	0.00101	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—H2AFZ—testicular cancer	7.06e-05	0.000966	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—STK11—testicular cancer	7.02e-05	0.00096	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KITLG—testicular cancer	6.5e-05	0.000889	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—H2AFZ—testicular cancer	6.19e-05	0.000847	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—STK11—testicular cancer	6.16e-05	0.000842	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—FGFR3—testicular cancer	5.88e-05	0.000805	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KITLG—testicular cancer	5.7e-05	0.000779	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—FGFR3—testicular cancer	5.69e-05	0.000778	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—FGFR3—testicular cancer	5.69e-05	0.000778	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—FGFR3—testicular cancer	5.65e-05	0.000773	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—FGFR3—testicular cancer	5.46e-05	0.000747	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—FGFR3—testicular cancer	5.46e-05	0.000747	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—HPGDS—testicular cancer	5.45e-05	0.000745	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—KIT—testicular cancer	5.4e-05	0.000739	CbGpPWpGaD
Loperamide—CALM3—Metabolism—HPGDS—testicular cancer	5.3e-05	0.000725	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—H2AFZ—testicular cancer	5.23e-05	0.000716	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—KIT—testicular cancer	5.22e-05	0.000715	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—KIT—testicular cancer	5.22e-05	0.000715	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—STK11—testicular cancer	5.2e-05	0.000712	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—KIT—testicular cancer	5.19e-05	0.000709	CbGpPWpGaD
Loperamide—CALM1—Metabolism—HPGDS—testicular cancer	5.13e-05	0.000701	CbGpPWpGaD
Loperamide—CALM2—Metabolism—HPGDS—testicular cancer	5.13e-05	0.000701	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—KIT—testicular cancer	5.02e-05	0.000686	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KIT—testicular cancer	5.02e-05	0.000686	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—FGFR3—testicular cancer	4.83e-05	0.00066	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KITLG—testicular cancer	4.82e-05	0.000659	CbGpPWpGaD
Loperamide—CALM3—Disease—H2AFZ—testicular cancer	4.63e-05	0.000633	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—HPGDS—testicular cancer	4.61e-05	0.000631	CbGpPWpGaD
Loperamide—CALM3—Immune System—KITLG—testicular cancer	4.61e-05	0.00063	CbGpPWpGaD
Loperamide—CALM1—Disease—H2AFZ—testicular cancer	4.48e-05	0.000612	CbGpPWpGaD
Loperamide—CALM2—Disease—H2AFZ—testicular cancer	4.48e-05	0.000612	CbGpPWpGaD
Loperamide—CALM2—Immune System—KITLG—testicular cancer	4.46e-05	0.00061	CbGpPWpGaD
Loperamide—CALM1—Immune System—KITLG—testicular cancer	4.46e-05	0.00061	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KIT—testicular cancer	4.43e-05	0.000606	CbGpPWpGaD
Loperamide—CALM3—Disease—KITLG—testicular cancer	4.26e-05	0.000582	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—FGFR3—testicular cancer	4.23e-05	0.000579	CbGpPWpGaD
Loperamide—CALM1—Disease—KITLG—testicular cancer	4.12e-05	0.000563	CbGpPWpGaD
Loperamide—CALM2—Disease—KITLG—testicular cancer	4.12e-05	0.000563	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—HPGDS—testicular cancer	4.02e-05	0.00055	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—STK11—testicular cancer	3.96e-05	0.000541	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KIT—testicular cancer	3.89e-05	0.000532	CbGpPWpGaD
Loperamide—CALM3—Metabolism—STK11—testicular cancer	3.85e-05	0.000527	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—HPGDS—testicular cancer	3.79e-05	0.000518	CbGpPWpGaD
Loperamide—CALM1—Metabolism—STK11—testicular cancer	3.73e-05	0.00051	CbGpPWpGaD
Loperamide—CALM2—Metabolism—STK11—testicular cancer	3.73e-05	0.00051	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—FGFR3—testicular cancer	3.58e-05	0.000489	CbGpPWpGaD
Loperamide—CALM3—Immune System—FGFR3—testicular cancer	3.43e-05	0.000469	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—STK11—testicular cancer	3.35e-05	0.000458	CbGpPWpGaD
Loperamide—CALM1—Immune System—FGFR3—testicular cancer	3.31e-05	0.000453	CbGpPWpGaD
Loperamide—CALM2—Immune System—FGFR3—testicular cancer	3.31e-05	0.000453	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KIT—testicular cancer	3.29e-05	0.000449	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—H2AFZ—testicular cancer	3.24e-05	0.000443	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—STK11—testicular cancer	3.22e-05	0.000441	CbGpPWpGaD
Loperamide—CALM3—Disease—FGFR3—testicular cancer	3.16e-05	0.000433	CbGpPWpGaD
Loperamide—CALM3—Immune System—KIT—testicular cancer	3.15e-05	0.00043	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—H2AFZ—testicular cancer	3.13e-05	0.000429	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—H2AFZ—testicular cancer	3.13e-05	0.000429	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—STK11—testicular cancer	3.12e-05	0.000426	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—STK11—testicular cancer	3.12e-05	0.000426	CbGpPWpGaD
Loperamide—CALM1—Disease—FGFR3—testicular cancer	3.06e-05	0.000419	CbGpPWpGaD
Loperamide—CALM2—Disease—FGFR3—testicular cancer	3.06e-05	0.000419	CbGpPWpGaD
Loperamide—CALM2—Immune System—KIT—testicular cancer	3.04e-05	0.000416	CbGpPWpGaD
Loperamide—CALM1—Immune System—KIT—testicular cancer	3.04e-05	0.000416	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KITLG—testicular cancer	2.98e-05	0.000408	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—STK11—testicular cancer	2.92e-05	0.000399	CbGpPWpGaD
Loperamide—CALM3—Disease—KIT—testicular cancer	2.9e-05	0.000397	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KITLG—testicular cancer	2.88e-05	0.000394	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KITLG—testicular cancer	2.88e-05	0.000394	CbGpPWpGaD
Loperamide—CALM1—Disease—KIT—testicular cancer	2.81e-05	0.000384	CbGpPWpGaD
Loperamide—CALM2—Disease—KIT—testicular cancer	2.81e-05	0.000384	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—STK11—testicular cancer	2.75e-05	0.000376	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HPGDS—testicular cancer	2.48e-05	0.000339	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGFR3—testicular cancer	2.22e-05	0.000303	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGFR3—testicular cancer	2.14e-05	0.000293	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGFR3—testicular cancer	2.14e-05	0.000293	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KIT—testicular cancer	2.03e-05	0.000278	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KIT—testicular cancer	1.97e-05	0.000269	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KIT—testicular cancer	1.97e-05	0.000269	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—STK11—testicular cancer	1.8e-05	0.000246	CbGpPWpGaD
